Fig. 3.

SCH58261 blocked CGRP release from nociceptive endings. a Represented immunostaining of CGRP (red, arrowheads) in TRPV1⁺ neuronal niche (green, circled). The curves in the upper panels delineated the tumor area (T, blue). Scale bars, 50 μm. b Comparison of CGRP immunofluorescence intensity of each TRPV1-positive field (1 000 µm²) in the peri-tumor area represented, n = 16 random fields from 4 mice. c Comparison of CGRP immunofluorescence intensity of each TRPV1-positive field (1 000 µm²) in intra-tumor area. n = 16 random fields from 4 mice. d CGRP level in serum from healthy mice, tumor-carrying mice with or without 5 mg/kg SCH58261 treatment. n = 5 mice. e Relative transcription level of Calca in trigeminal ganglia of healthy mice, ipsilateral or contralateral side of tumor inoculation site, n = 3 mice. Statistical analysis was conducted using unpaired Student’s t-test (b, c, d, e)